FDA Approved Breast Cancer DNA Test by 23andMe May do More Harm than Good
By Joyce Bichler,
Breast Cancer Action
| 03. 07. 2018
Yesterday, the Food and Drug Administration (FDA) for the first time approved an at-home genetic testing kit without a doctor’s prescription to predict the risk of breast cancer. While there’s no doubt the move will be celebrated by some, the truth is that there is cause for serious concern. This decision by the FDA threatens to do more harm than good for women at risk of and living with breast cancer.
Most immediately, the 23andMe test approved for over-the-counter use looks at just three of the more than 1000 known BRCA1 and BRCA2 mutations. While these three specific mutations are the most common BRCA1 and BRCA2 mutations for people of Ashkenazi ancestry, they are not the most common BRCA mutations in the broader population, raising serious health equity concerns. This means that if you’re someone who receives a negative result from the 23andMe test, there is still the possibility that you may carry other harmful BRCA mutations that increase the risk of breast cancer.
At Breast Cancer Action, we’ve long argued that genetic testing should always be accompanied by independent...
Related Articles
By Pallab Gosh and Gwyndaf Hughes, BBC News | 06.26.2025
Work has begun on a controversial project to create the building blocks of human life from scratch, in what is believed to be a world first.
The research has been taboo until now because of concerns it could lead to...
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...